UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 30, 2008
OR
TRANSITION REPORT
PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition
period from________to_______
COMMISSION FILE
NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235
East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip
code)
(212) 573-2323
(Registrant's telephone number)
Indicate by check mark whether the registrant (1) has
filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports) and (2)
has been subject to such filing requirements for the past 90 days.
YES X NO
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer or a smaller
reporting company. See definitions of "large accelerated filer," "accelerated
filer" and "smaller reporting company" in Rule 12b-2 of the
Exchange Act (Check one):
Large accelerated filer X Accelerated
filer Non-accelerated
filer Smaller
reporting company
Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Exchange Act).
YES NO X
At April 30, 2008, 6,765,196,985 shares of the issuer's
voting common stock were outstanding.
FORM 10-Q
For the Quarter
Ended
March 30, 2008
Table
of Contents
PART I. FINANCIAL
INFORMATION
Page
Item 1.
Financial Statements
Condensed
Consolidated Statements of Income for the three months ended March 30, 2008,
and April 1, 2007
Condensed
Consolidated Balance Sheets as of March 30, 2008, and December 31, 2007
Condensed
Consolidated Statements of Cash Flows for the three months ended March 30,
2008, and April 1, 2007
Notes to
Condensed Consolidated Financial Statements
Review Report
of Independent Registered Public Accounting Firm
16
Item 2.
Management's
Discussion and Analysis of Financial Condition and Results of Operations
17
Item 3.
Quantitative
and Qualitative Disclosures About Market Risk
43
Item 4.
Controls and
Procedures
43
PART II. OTHER
INFORMATION
Item 1.
Legal
Proceedings
43
Item 1A.
Risk Factors
46
Item 2.
Unregistered
Sales of Equity Securities and Use of Proceeds
47
Item 3.
Defaults Upon
Senior Securities
47
Item 4.
Submission of
Matters to a Vote of Security Holders
48
Item 5.
Other
Information
48
Item 6.
Exhibits
49
Signature
50
PART
I - FINANCIAL INFORMATION
Item 1. Financial Statements.
PFIZER INC AND SUBSIDIARY
COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three
Months Ended
(millions, except per common share
data)
Mar. 30,
2008
April 1,
2007
Revenues
11,848
12,474
Costs and expenses:
Cost of sales(a)
1,986
1,887
Selling,
informational and administrative expenses(a)
3,492
3,361
Research and
development expenses(a)
1,791
1,665
Amortization of
intangible assets
779
815
Acquisition-related
in-process research and development charges
398
283
Restructuring
charges and acquisition-related costs
178
812
Other
(income)/deductions - net
(333)
(402)
Income from
continuing operations before provision for taxes on income and minority
interests
3,557
4,053
Provision for
taxes on income
763
689
Minority
interests
Income from
continuing operations
2,788
3,361
Discontinued
operations:
Loss from
discontinued operations - net of tax
(4)
--
Gains on sales
of discontinued operations - net of tax
--
31
Discontinued
operations - net of tax
(4)
31
Net income
2,784
3,392
Earnings per common share - basic:
Income from
continuing operations
0.41
0.48
Discontinued
operations - net of tax
--
--
Net income
0.41
0.48
Earnings per common share -
diluted:
Income from
continuing operations
0.41
0.48
Discontinued
operations - net of tax
--
--
Net income
0.41
0.48
Weighted-average
shares used to calculate earnings per common share:
Basic
6,739
7,051
Diluted
6,762
7,075
Cash dividends paid per common
share
0.32
0.29
(a)
Exclusive of amortization of
intangible assets, except as disclosed in Note 8B. Goodwill and Other
Intangible Assets: Other Intangible Assets.
See accompanying
Notes to Condensed Consolidated Financial Statements.
PFIZER
INC AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(millions
of dollars)
Mar. 30,
2008*
Dec. 31,
2007**
ASSETS
Cash and cash equivalents
2,013
3,406
Short-term investments
26,615
22,069
Accounts receivable, less allowance
for doubtful accounts
10,432
9,843
Short-term loans
777
617
Inventories
5,148
5,302
Prepaid expenses and taxes
5,939
5,498
Assets held for sale
87
114
Total current assets
51,011
46,849
Long-term
investments and loans
4,511
4,856
Property, plant and equipment, less
accumulated depreciation
15,383
15,734
Goodwill
21,556
21,382
Identifiable
intangible assets, less accumulated amortization
19,896
20,498
Other assets,
deferred taxes and deferred charges
6,193
5,949
Total assets
118,550
115,268
LIABILITIES
AND SHAREHOLDERS' EQUITY
Short-term borrowings, including
current portion of long-term debt
8,909
5,825
Accounts payable
1,909
2,270
Dividends payable
2,163
Income taxes payable
1,221
1,380
Accrued compensation and related
items
1,622
1,974
Other current liabilities
8,020
8,223
Total current liabilities
21,682
21,835
Long-term debt
8,143
7,314
Pension benefit
obligations
2,550
2,599
Postretirement
benefit obligations
1,703
1,708
Deferred taxes
7,441
7,696
Other taxes
payable
6,284
6,246
Other
noncurrent liabilities
3,187
2,746
Total liabilities
50,990
50,144
Minority interests
143
114
Preferred stock
86
93
Common stock
443
442
Additional
paid-in capital
70,001
69,913
Employee
benefit trust, at fair value
(459)
(550)
Treasury stock
(56,883)
(56,847)
Retained
earnings
52,436
49,660
Accumulated
other comprehensive income
1,793
2,299
Total shareholders' equity
67,417
65,010
Total liabilities and shareholders'
equity
118,550
115,268
* Unaudited.
** Condensed from audited
financial statements.
See accompanying
Notes to Condensed Consolidated Financial Statements.
PFIZER INC AND
SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Three
Months Ended
(millions of dollars)
Mar. 30,
2008
April 1,
2007
Operating
Activities:
Net income
2,784
3,392
Adjustments to
reconcile net income to net cash provided by operating activities:
Depreciation
and amortization
1,487
1,271
Share-based
compensation expense
101
141
Acquisition-related
in-process research and development charges
398
283
Gains on
disposals
(23)
(7)
Gains on sales
of discontinued operations
--
(40)
Deferred taxes
from continuing operations
544
(268)
Other non-cash
adjustments
242
58
Changes in
assets and liabilities (net of businesses acquired and divested)
(2,262)
(3,587)
Net cash provided by operating
activities
3,271
1,243
Investing Activities:
Purchases of
property, plant and equipment
(483)
(329)
Purchases of
short-term investments
(10,648)
(5,617)
Proceeds from sales
and redemptions of short-term investments
6,817
11,819
Purchases of long-term
investments
(498)
(1,158)
Proceeds from sales
and redemptions of long-term investments
42
Purchases of
other assets
(14)
(2)
Proceeds from
the sales of businesses, products and product lines
--
Acquisitions,
net of cash acquired
(610)
(463)
Other investing
activities
(90)
Net cash (used in)/provided by
investing activities
(5,484)
4,271
Financing Activities:
Increase in
short-term borrowings, net
4,899
162
Principal
payments on short-term borrowings
(1,955)
(729)
Proceeds from
issuances of long-term debt
602
19
Principal
payments on long-term debt
(561)
(58)
Purchases of
common stock
--
(2,500)
Cash dividends
paid
(2,138)
(2,032)
Stock option
transactions and other
290
Net cash provided
by/(used in) financing activities
848
(4,848)
Effect of
exchange-rate changes on cash and cash equivalents
(28)
(1)
Net (decrease)/increase
in cash and cash equivalents
(1,393)
665
Cash and cash
equivalents at beginning of period
3,406
1,827
Cash and cash
equivalents at end of period
2,013
2,492
Supplemental
Cash Flow Information:
Cash paid
during the period for:
Income taxes
640
2,424
Interest
166
170
See accompanying
Notes to Condensed Consolidated Financial Statements.
PFIZER
INC AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of
Presentation
We prepared the condensed
consolidated financial statements following the requirements of the Securities
and Exchange Commission (SEC) for interim reporting. As permitted under those
rules, certain footnotes or other financial information that are normally
required by accounting principles generally accepted in the United States of
America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and
operating results for subsidiaries operating outside the U.S. are as of and for
the three-month periods ended February 24, 2008, and February 25, 2007.
Revenues, expenses, assets and
liabilities can vary during each quarter of the year. Therefore, the results
and trends in these interim financial statements may not be representative of
those for the full year.
We are responsible for the unaudited
financial statements included in this document. The financial statements
include all normal and recurring adjustments that are considered necessary for
the fair presentation of our financial position and operating results.
The information included in this
Quarterly Report on Form 10-Q should be read in conjunction with the
consolidated financial statements and accompanying notes included in Pfizer's
Annual Report on Form 10-K for the year ended December 31, 2007.
Note 2. Adoption of New
Accounting Policies
As of January 1, 2008, we adopted on
a prospective basis certain required provisions of Statement of Financial
Accounting Standards (SFAS) No. 157, Fair Value Measurements, as amended
by Financial Accounting Standards Board (FASB) Financial Staff Position (FSP) No. 157-2,
Effective Date of FASB Statement No. 157. Those provisions relate to our
financial assets and liabilities carried at fair value and our fair value
disclosures related to financial assets and liabilities. SFAS 157 defines fair
value, expands related disclosure requirements and specifies a hierarchy of
valuation techniques based on the nature of the inputs used to develop the fair
value measures. Fair value is defined as the price that would be received to
sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. There are three levels of inputs
to fair value measurements - Level 1, meaning the use of quoted prices for
identical instruments in active markets; Level 2, meaning the use of quoted
prices for similar instruments in active markets or quoted prices for identical
or similar instruments in markets that are not active or are directly or
indirectly observable; and Level 3, meaning the use of unobservable inputs.
Observable market data should be used when available.
Many, but not all, of our financial
instruments are carried at fair value. For example,
substantially all of our cash equivalents, short-term investments and long-term
investments are classified as available-for-sale securities and are carried at
fair value, with unrealized gains and losses, net of tax, reported in Other
comprehensive income. Derivative financial instruments are carried
at fair value, with changes in fair value reported in various balance sheet
categories (see both Note 10 D. Financial Instruments: Derivative Financial
Instruments and Hedging Activities in our 2007 Annual Report, and Note 6C.
Financial Instruments: Derivative Financial Instruments and Hedging Activities in
this Quarterly Report) and ultimately, in Other (income)/deductions - net.
Virtually all of our valuation measurements are Level 2 measurements. The
adoption of SFAS 157 did not have a significant impact on our consolidated financial
statements. We did not elect to adopt SFAS 157 for acquired non-financial
assets and assumed non-financial liabilities.
Emerging Issues Task Force (EITF)
Issue No. 07-3, Accounting for Nonrefundable Advance Payments for Goods or
Services to Be Used in Future Research and Development Activities, became
effective for new contracts entered into on or after January 1, 2008. EITF
Issue No. 07-3 requires that non-refundable advance payments for goods and
services that will be used in future research and development (R&D)
activities be expensed when the R&D activity has been performed or
when the R&D goods have been received rather than when the payment is made.
The adoption of EITF Issue No. 07-3 did not have a significant impact on our consolidated
financial statements.
Note 3. Acquisitions
During the first quarters of 2008 and
2007, we acquired the following:
In January 2008, we acquired CovX,
a privately held biotherapeutics company specializing in preclinical oncology
and metabolic research and the developer of a biotherapeutics technology platform
that we expect will enhance our biologic portfolio. Also in January 2008, we
acquired all the outstanding shares of Coley Pharmaceutical Group, Inc., a
biopharmaceutical company specializing in vaccines and drug candidates
designed to fight cancers, allergy and asthma disorders, and autoimmune
diseases, for approximately $230 million. In connection with these and two
smaller acquisitions related to Animal Health, we recorded $398 million in Acquisition-related